All-oral phase II trial of ACH 3422 in combination with ACH 3102 in patients with hepatitis C

Trial Profile

All-oral phase II trial of ACH 3422 in combination with ACH 3102 in patients with hepatitis C

Planning
Phase of Trial: Phase II

Latest Information Update: 05 Mar 2015

At a glance

  • Drugs ACH 3422 (Primary) ; Odalasvir (Primary)
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Mar 2015 SVR4 results are expected in the second half of 2015, according to an Achillion media release.
    • 05 Mar 2015 Planned initiation date changed from 1 Dec 2014 to 1 Jun 2015, according to an Achillion media release.
    • 15 Aug 2014 This trial is expected to be initiated before the end of 2014, according to an Achillion media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top